drugset / Trial / NCT06048393
SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People
RandomizedParallel-groupDouble-blindPrevention
Summary
To evaluate the safety, tolerance, local drug content and neutralization activity in nasal cavity, systemic exposure level and immunogenicity of novel coronavirus broad-spectrum neutralizing antibody SA55 nasal spray.
Timeline
- Start
- 2023-05-31
- Primary completion
- 2023-09-30
- Completion
- 2023-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SA55 | Protein / enzyme biologic | 5 mg | Intranasal |
| Subject | SA55 | Protein / enzyme biologic | 10 mg | Intranasal |